GC
KYMR icon

Guggenheim Capital’s Kymera Therapeutics KYMR Stock Holding History

Guggenheim Capital’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.32M Sell
11,518
-1,570
-12% -$135K 0.01% 894
2026
Q1 		$1.09M Buy
13,088
+2,781
+27% +$220K 0.01% 964
2025
Q4 		$802K Buy
+10,307
New +$696K 0.01% 1047

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Guggenheim Capital's KYMR Position: Q2 2026 in Review

Guggenheim Capital reduced its Kymera Therapeutics (KYMR) stake by 12% in Q2 2026, selling an estimated $135K and leaving 11,518 shares worth $1.32M. The position accounts for 0.01% of the portfolio, ranked #894.

Guggenheim Capital first reported a position in KYMR in Q4 2025 and has held it in 3 quarters since. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Guggenheim Capital held 11,518 shares of Kymera Therapeutics worth $1.32M as of Q2 2026.
  • Guggenheim Capital sold 1,570 Kymera Therapeutics shares in Q2 2026, an estimated $135K.
  • Kymera Therapeutics made up 0.01% of Guggenheim Capital's portfolio in Q2 2026, its #894 holding.
  • Guggenheim Capital first reported a position in Kymera Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.